Abstract
Prostate cancer (PCa) is the second leading cause of cancer death among men. Approximately patients 30% show recurrence of the disease after treatment, who initially responds to androgen deprivation therapy (ADT), and may progress to a therapy resistance PCa, turning into castration-resistance prostate cancer (CRPC). Several therapies are being developed in order to delay or prevent the d…